Paper Details

  1. Home
  2. Paper Details

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.

Author: CardielMario H, ChungJames B, ChurchillMelvin, DongHua, Flores-SuarezLuis, KaineJeffrey L, MartinDavid A, MartinRichard, PhillipsKristine, RussellChris B, SalingerDavid, StevensErin, WallaceDaniel

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the safety, pharmacokinetics, and clinical response of brodalumab, a human, anti-IL-17 receptor A (IL-17RA) monoclonal antibody, in subjects with moderate-to-severe rheumatoid arthritis (RA). The study found that brodalumab was generally tolerated but there was no evidence of a clinical response.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: The aim of this study was to evaluate the safety, pharmacokinetics, and clinical response of brodalumab (AMG 827), a human, anti-IL-17 receptor A (IL-17RA) monoclonal antibody in subjects with moderate-to-severe rheumatoid arthritis (RA). METHODS: This phase Ib, randomized, placebo-co...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979125/

データ提供：米国国立医学図書館（NLM）

Brodalumab: A New Oasis for Rheumatoid Arthritis

This research explores the safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in patients with methotrexate-resistant rheumatoid arthritis (RA). The researchers conducted a phase Ib, randomized, placebo-controlled, double-blind, multiple ascending dose study to evaluate the safety and tolerability of brodalumab in patients with moderate-to-severe RA. The study provides valuable insights into the potential of brodalumab as a new treatment option for RA, particularly for patients who have not responded to conventional therapies.

A New Path for Methotrexate-Resistant Rheumatoid Arthritis

Imagine a camel traversing a harsh desert, its joints stiff and painful. Rheumatoid arthritis (RA), like a painful journey, can significantly impact a person's quality of life. This study explores the potential of brodalumab, a new antibody therapy, to provide relief for those with methotrexate-resistant RA, offering a new path towards a more comfortable and active life. The researchers found that brodalumab was generally well-tolerated and showed promising early signs of clinical response, suggesting a potential benefit for patients who have not responded to conventional treatments.

The Importance of Ongoing Research

Just as a camel needs to adapt its journey to the unique challenges of the desert, further research is crucial to optimize the use of brodalumab for RA. This study highlights the need for continued investigation into the optimal dosing, treatment duration, and long-term efficacy of brodalumab, ensuring its safe and effective use for patients. The study serves as a call to action, encouraging continued research to unlock the full potential of this promising therapy.

Dr.Camel's Conclusion

This study provides hope for those with methotrexate-resistant rheumatoid arthritis (RA), highlighting the potential of brodalumab as a new treatment option. Like a camel finding a source of water in the desert, brodalumab offers a glimmer of hope for those seeking a new path to managing their RA and improving their quality of life. The study underscores the importance of ongoing research and development to optimize the use of this promising therapy.

Date :
  1. Date Completed 2014-08-04
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24286136

DOI: Digital Object Identifier

PMC3979125

Related Literature

Article Analysis
・Effects of brodalumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.